Intravenous magnesium sulphate in children with acute wheeze : a nationwide survey

OBJECTIVE: Dutch guidelines recommend to consider intravenous magnesium sulfate (iv MgSO4) as a treatment option in case of failure of first line treatment in both children with exacerbations of acute episodic viral wheeze (AEVW) and acute asthma (AA). The implications on the actual use of iv MgSO4 iv in daily practice in both groups are unknown. Therefore, we conducted a cross-sectional nationwide survey to evaluate the use of iv MgSO4 in children with AEVW and AA.

METHODS: A questionnaire was handed out to pediatricians and pediatric residents in one academic and six community teaching hospitals.

RESULTS: In 111 respondents, 76% reported regular use of iv MgSO4 in children with AEVW and 96% in children with AA. In total 89% and 93% of users were convinced iv MgSO4 was effective in children with AEVW and AA, respectively. Adverse effects, mainly hypotension, were identified by 23% and 17% of users in AEVW and AA, respectively. Most common reasons not to give MgSO4 were lack of evidence and small amount of studies.

CONCLUSIONS: IV MgSO4 is reported to be widely used in Dutch practice in both young children with AEVW and older children with AA by respondents, while the national guidelines advise only to consider this treatment option.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:58

Enthalten in:

The Journal of asthma : official journal of the Association for the Care of Asthma - 58(2021), 11 vom: 01. Nov., Seite 1444-1450

Sprache:

Englisch

Beteiligte Personen:

van Weelden, Marlon [VerfasserIn]
van Ewijk, Bart E [VerfasserIn]
Plötz, Frans B [VerfasserIn]

Links:

Volltext

Themen:

7487-88-9
Acute asthma
Acute episodic viral wheeze
Asthma exacerbation
Children
Exacerbation
Journal Article
Magnesium Sulfate
Magnesium sulfate

Anmerkungen:

Date Completed 03.01.2022

Date Revised 03.01.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1080/02770903.2020.1805752

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM31322059X